Oculus Innovative Sciences – Global Rights for Endotracheal Tube

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS). Last Market Price: 1.55, Change: 0.00, % Change: (-0.19%). Shares trade in the range of 1.43 – 1.85 dollars. It has a market capitalization of 41.45M dollars, making it a Small Cap Stock and has 26.79M outstanding shares. The company has a beta of 2.09, indicating, the stock to be more volatile than the market. As per the most recent quarterly report, the net income per share (EPS) is -0.29. It operates in Healthcare sector and belongs to Biotechnology and Drugs industry. Percentage shares held by institutional investors is 6%. The company has a 52 week high of $ 2.65 and a 52 week low of $ 0.97. Average volumes of shares traded daily are 49,573. Volume traded in the last session was at 575,184, 11.60 times the average volume.

• Company announces “Oculus Innovative Sciences licenses Global Rights for Endotracheal Tube from National Institutes of Health to reduce Ventilator-Associated pneumonia”

For Q2 (Jun ’11), It had a Net profit margin of -73.98%, an Operating margin of -68.64%. Other Key stats and ratios are : Return on average assets of -97.62%, Return on average equity of -835.62%. The organization has an employee strength of 31

Consensus Recommendation is a Buy.

Estimate for sales for the Year Ending Mar-12 show a mean of 13.74 million dollars, an estimate high of 14.28 million dollars and an estimate low of 13.20 million dollars. A year ago the figures stood at 19.30 million dollars.

Estimate for sales for the Year Ending Mar-13 show a mean of 25.58 million dollars, an estimate high of 29.30 million dollars and an estimate low of 22.91 million dollars. A year ago the figures stood at 29.44 million dollars.

Estimate for EPS for the Year Ending Mar-12 show a mean of -0.21 dollars, an estimate high of -0.20 dollars and an estimate low of -0.23 dollars. A year ago the figures stood at -0.14 dollars.

Estimate for EPS for the Year Ending Mar-13 show a mean of 0.00 dollars, an estimate high of 0.05 dollars and an estimate low of -0.06 dollars. A year ago the figures stood at 0.01 dollars.

Sales for Quarter Ending Jun-11 was estimated at 2.79 million dollars, however the actual sales figure stood at 2.94 million dollars, 0.15 million dollars more than estimates.

Sales for Quarter Ending Mar-11 was estimated at 2.71 million dollars, however the actual sales figure stood at 2.71 million dollars, 0 million dollars less than estimates.

Post Written By: Ed Liston Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht.